Not applicableApproved For MarketingNCT02477891
What this trial is testing
Early Access Treatment With Daratumumab for (Relapsed or Refractory) Multiple Myeloma
Who this might be right for
Multiple Myeloma
Janssen Research & Development, LLC
Showing 20 of 53 results